MedTrace Logo

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

NCT00383422 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2010-01-28

No results posted yet for this study

Summary

The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Arzoxifene

20 mg, oral, tablet, once a day for 52 weeks

DRUG

Raloxifene

60 mg, oral, tablet, once a day for 52 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • France
  • Italy
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383422 on ClinicalTrials.gov